Veracyte, INC.: directors' dealings · United States · SEC (Form 4)

About Veracyte, INC.

Veracyte, Inc. (NYSE/NASDAQ: VCYT) is a U.S.-listed precision diagnostics company headquartered in South San Francisco, California, with additional offices in San Diego, Austin, Texas, and Haifa, Israel. The company was built around a clear clinical mission: improve cancer care by providing molecular answers that help clinicians avoid unnecessary invasive procedures and get patients to the right treatment faster. Veracyte describes itself as a global diagnostics company focused primarily on oncology and certain interstitial lung diseases, with an international operational footprint and a growing evidence base supporting clinical adoption. ([veracyte.com](https://www.veracyte.com/company/)) Veracyte’s business model is centered on a diagnostics platform that combines genomic and clinical data, bioinformatics, artificial intelligence, and evidence generation. This platform approach is important because it supports test performance, reimbursement durability, and guideline adoption. The company’s core commercial products include Afirma, which is widely associated with thyroid nodule assessment, and the Decipher franchise, a genomic classifier used prominently in prostate cancer and broader urologic oncology applications. Veracyte also highlights emerging pipeline and platform initiatives, including TrueMRD and planned Prosigna LDT-related launches, indicating continued investment in expanding its addressable market across the cancer care continuum. ([investor.veracyte.com](https://investor.veracyte.com/)) From a competitive standpoint, Veracyte differentiates itself through a high-value diagnostic niche: helping physicians make more confident decisions while reducing unnecessary procedures and associated costs. Rather than competing as a broad-based in vitro diagnostics vendor, the company has positioned itself as a leader in evidence-backed oncology diagnostics, where clinical utility, reimbursement, and physician trust are key barriers to entry. Management has also emphasized that growth is being driven primarily by Decipher and Afirma, underlining the importance of these franchises to the investment case. ([investor.veracyte.com](https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-fourth-quarter-and-full-year-2025-financial)) Recent developments have reinforced the growth narrative. In November 2025, Veracyte reported strong testing-revenue momentum and highlighted a Cell publication from the STAMPEDE trial showing that Decipher Prostate can predict chemotherapy benefit in metastatic prostate cancer, while also launching the Afirma v2 transcriptome to improve operational efficiency and serve as a platform for future products. In February 2026, the company reported full-year 2025 results, with strong double-digit growth in both Decipher and Afirma and more than 45,000 patients served with its core testing business in the quarter. These updates suggest a business that is scaling well while investing in its next wave of diagnostic innovation. ([investor.veracyte.com](https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-third-quarter-2025-financial-results))